Glaukos Corporation research snapshot
GKOS AI stock analysis currently sees Glaukos as a differentiated ophthalmic medical technology and pharmaceutical company whose iDose TR glaucoma therapy and Epioxa corneal therapy could expand the addressable market. At the July 12, 2026 data cutoff, the July 10 close was $152.72 and the mechanically calculated market capitalization was about $8.97 billion using 58.71 million shares. Q1 2026 revenue rose 41% to $150.6 million and management raised 2026 revenue guidance to $620 million to $635 million, but GAAP losses, negative trailing free cash flow, share issuance, reimbursement risk, and a 16.26x price-to-sales ratio leave little room for execution mistakes. This GKOS AI stock analysis uses scenarios rather than a certain price prediction and is for informational use only, not investment advice.
Current price
$152.72
Market cap
$8.97 billion calculated market cap
AI score
61 / 100
Rating
High-growth ophthalmic platform with strong adoption signals, ongoing losses, dilution, and a demanding valuation
Trend status
Strong but extended: above the 50-day and 200-day averages, near the 52-week high, with RSI approaching overbought territory
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Glaukos sells ophthalmic devices and pharmaceuticals for glaucoma, corneal disorders, and retinal disease. Customers pay for products that can improve procedures, reduce treatment burden, or create a new delivery method for chronic eye care. | High |
| Moat | The moat is built from regulatory approvals, clinical evidence, physician training, commercial relationships, patents, and the iStent and iDose platforms. Switching costs are meaningful in procedure workflows, but competing therapies and reimbursement decisions can still weaken pricing power. | Medium-high |
| Management | CEO Thomas Burns has led Glaukos since 2002 and has built multiple ophthalmic businesses. The next management test is turning iDose TR and Epioxa adoption into GAAP profitability and cash generation without excessive equity dilution. | Medium |
| Financial trend | FY2025 revenue rose 32.3% to $507.4 million, while GAAP net loss widened to $187.7 million after a $112.9 million Avedro-related impairment. Q1 2026 revenue rose 41% to $150.6 million, but the company still reported a $19.8 million net loss. | High |
| Valuation | At $152.72, standardized TTM data showed 16.26x sales, 13.28x book value, and negative earnings and free cash flow. The stock is priced for sustained high growth and a large future profit step-up rather than current earnings power. | High |
| Technical trend | The price was above the 50-day average of $132.37 and the 200-day average of $111.81, with RSI near 67.79 and the price close to the $156.60 52-week high. Momentum is strong, but the setup is extended. | Medium |
| Risk level | The main risks are product adoption, reimbursement, regulatory approval, clinical outcomes, manufacturing concentration, litigation, future share issuance, operating losses, and valuation compression if growth slows. | High |
| AI confidence | Historical facts and calculation outputs have high confidence. Forward profitability, long-term product adoption, and price outcomes have lower confidence because the business has not yet produced sustained GAAP earnings or free cash flow. | High data confidence |
| Investment certainty | Low to medium certainty. The products are differentiated, but the investment case depends on future reimbursement and commercial execution being strong enough to support a premium multiple. | Low-medium |
GKOS AI stock forecast
The GKOS AI stock forecast uses a $152.72 reference price and a StockAnalysis 2027 EPS forecast of $0.44 as a forward starting proxy, because current GAAP EPS is negative. Using the financial rigor tool with 60%, 40%, and 10% annual growth assumptions and 150x, 120x, and 80x terminal multiples produced illustrative three-year values of $270.30, $144.90, and $46.90. These are sensitivity outputs, not company guidance or guaranteed targets. The wide spread shows how much the current price depends on future profitability.
$220 to $300
More likely if iDose TR adoption expands across glaucoma procedures, Epioxa gains reimbursement and physician use after its J-code becomes effective, revenue stays near or above the mid-20% growth path, and operating leverage creates durable positive cash flow.
$130 to $175
More likely if 2026 guidance is met, iDose TR and Epioxa grow but require continued sales and clinical investment, the 2027 EPS forecast begins to materialize, and the market keeps a premium multiple near the current analyst target range of $138 to $170.
$45 to $100
More likely if reimbursement is slower than expected, clinical or regulatory milestones slip, non-iDose products weaken, losses persist, dilution increases, or investors revalue GKOS closer to profitable medtech peers rather than a platform-growth multiple.
GKOS AI technical analysis
GKOS AI technical analysis is strong but extended at the July 12, 2026 data cutoff. The July 10 close was $152.72, above both major moving averages and only about 2.5% below the cited 52-week high of $156.60. RSI near 67.79 signals positive momentum that is approaching, but has not crossed, a conventional overbought threshold. This is a static snapshot and does not fetch request-time chart data.
| Level | Value | Why it matters |
|---|---|---|
| Reference price | $152.72 | Macrotrends and StockAnalysis reported the July 10, 2026 closing price. The market was closed at the July 12 data cutoff. |
| Near support | $145 to $150 | This is a planning zone below the July 10 close and should be confirmed against fresh daily closes and volume. It is not a guaranteed floor. |
| 50-day moving average | $132.37 | StockAnalysis listed the 50-day average in its July 10 technical snapshot. A sustained break below it would weaken the intermediate trend. |
| 200-day moving average | $111.81 | StockAnalysis listed the 200-day average in the same snapshot. This is the deeper trend reference and a potential long-term invalidation level. |
| Near resistance | $156.60 | The cited 52-week high is the first visible resistance. A breakout needs volume and fundamental confirmation because price is already extended. |
| Upper resistance | $161.22 | Macrotrends cited the all-time high closing price on January 23, 2025. It is an historical reference, not a forecast. |
| Momentum | RSI 67.79, positive and near overbought | StockAnalysis reported a 14-day RSI near 67.79. Momentum can remain strong, so RSI alone is not a sell signal. |
| Volume | 20-day average near 884,257 shares | Compare a move through $156.60 with a fresh completed-session volume reading rather than relying on the static average. |
| Invalidation | Sustained close below $111.81 | A decisive loss of the 200-day average would invalidate the strong long-term trend setup and require a new fundamental review. |
GKOS AI trading strategy
The GKOS AI trading strategy is a rules-based research framework, not personalized advice. Pair it with live chart data, the next earnings release, reimbursement updates, product adoption, cash flow, share count, and a defined invalidation condition.
Watch for a decisive move above $156.60 with volume near or above the 20-day average, followed by evidence that iDose TR and Epioxa adoption support the revenue path. A successful retest can be more informative than a single intraday breakout.
A failed breakout followed by a close below the selected near-support zone should invalidate the short-term trend setup. Do not treat the 52-week high as a guaranteed launch point.
If GKOS pulls back toward $132.37 without a new product, reimbursement, or clinical shock, compare price action with revenue guidance, cash burn, gross margin, and share issuance before treating the pullback as a valuation reset.
Do not average down solely because the price is below a recent high. The 200-day average near $111.81 is a deeper risk reference, not a promise of support.
Track iDose TR procedures and net sales, Epioxa reimbursement and account starts, U.S. and international glaucoma sales, corneal health sales, gross margin, operating loss, free cash flow, R&D, cash runway, and diluted shares outstanding.
Reduce confidence when revenue growth depends on higher spending without improving cash conversion, when dilution accelerates, or when reimbursement and clinical evidence fail to support the premium valuation.
Investment research summary
Glaukos converts ophthalmic research, regulatory approvals, physician adoption, and commercial support into procedure and pharmaceutical revenue. The customer pays for a treatment that can improve glaucoma management or corneal cross-linking workflow, not for a generic commodity device.
The moat is strongest where clinical evidence, FDA approvals, patents, physician familiarity, reimbursement codes, and product training reinforce each other. It is not a network-effect business, and competitors can challenge Glaukos with alternative devices, drugs, procedures, and pricing.
The thesis fails if iDose TR adoption slows, Epioxa reimbursement does not translate into procedures, clinical or regulatory outcomes disappoint, non-iDose products decline, or the company spends heavily without reaching cash profitability. The largest analytical error would be treating a strong Q1 as proof of a fully proven platform.
Thomas Burns has led Glaukos since 2002 and has long ophthalmic operating experience. Management has built a portfolio through internal development and acquisitions, but investors should judge capital allocation by profitable growth, dilution control, litigation discipline, and the conversion of product adoption into free cash flow.
Aging populations, chronic glaucoma, procedure migration, and interest in sustained or dropless therapy support a long-term ophthalmic opportunity. The industry is still shaped by FDA review, clinical evidence, payer coverage, physician habits, hospital budgets, and competitive alternatives.
At 16.26x TTM sales and with negative TTM earnings and free cash flow, GKOS has little traditional valuation support. The margin of safety must come from future profitable growth, not current book value or cash flow. The $8.97 billion market value assumes that the new product platforms become materially more profitable than the current financial statements show.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| GKOS reference price | $152.72 regular-session close on July 10, 2026 | Macrotrends and StockAnalysis market data | July 12, 2026 |
| Market capitalization | $8.97 billion calculated as $152.72 times 58.71 million shares. StockAnalysis reported $8.97 billion on July 8, 2026. Financial rigor deviation was 0.04%. | Financial rigor market-cap verification and StockAnalysis | July 12, 2026 |
| Shares outstanding | 58.733911 million shares as of April 28, 2026 in the SEC 10-Q; StockAnalysis showed 58.71 million. The cross-check variance was 0.04% using the underlying values. | Glaukos Q1 2026 Form 10-Q and StockAnalysis | July 12, 2026 |
| FY2025 financial trend | Revenue $507.442 million, gross profit $395.628 million, operating loss $199.6 million, net loss $187.69 million, and standardized free cash flow negative $39.06 million. Revenue increased 32.3% from 2024. | Glaukos 2025 Form 10-K, Macrotrends, and StockAnalysis financials | July 12, 2026 |
| Q1 2026 operating results | Net sales $150.571 million, gross margin 78%, operating loss $19.856 million, net loss $19.783 million, and non-GAAP net loss $10.415 million. Revenue increased 41% year over year. | Glaukos Q1 2026 results release and SEC 8-K exhibit | July 12, 2026 |
| Product and geographic mix | FY2025 U.S. glaucoma sales were $298.6 million, international glaucoma sales were $122.5 million, and corneal health sales were $86.4 million. Q1 2026 U.S. glaucoma sales were $93.5 million, international glaucoma sales $35.8 million, and corneal health sales $21.3 million. | Glaukos 2025 Form 10-K and Q1 2026 Form 10-Q | July 12, 2026 |
| Cash and debt | Cash, short-term investments, and restricted cash were $280.519 million at March 31, 2026. Glaukos reported no debt in its Q1 release, while standardized StockAnalysis data counted $105.87 million of finance and other lease-related debt, producing a net cash view that depends on debt definition. | Glaukos Q1 2026 Form 10-Q, Q1 release, and StockAnalysis | July 12, 2026 |
| Management ownership and incentives | The 2026 proxy reported beneficial ownership of 2,577,586 shares, or 4.4%, for CEO Thomas Burns and 3,529,874 shares, or 5.9%, for all executive officers and directors as a group, using the April 2, 2026 share count. StockAnalysis separately reported insider ownership of 3.61%, so the definitions and dates should not be treated as identical. | Glaukos 2026 proxy and StockAnalysis statistics | July 12, 2026 |
| 2026 revenue guidance | $620 million to $635 million, raised from the prior $600 million to $620 million range after Q1 2026. | Glaukos Q1 2026 financial results release | July 12, 2026 |
| Valuation snapshot | At $152.72, financial_rigor.py calculated 16.26x price to sales using $9.39 TTM revenue per share, 13.28x price to book, and negative earnings and free cash flow ratios because TTM EPS was negative $3.28 and FCF per share was negative $0.31. | StockAnalysis statistics and financial_rigor.py verify-valuation | July 12, 2026 |
| Technical snapshot | 50-day moving average $132.37, 200-day moving average $111.81, RSI 67.79, beta 0.75, 20-day average volume 884,257 shares, 52-week range $73.16 to $156.60, and 52-week change +45.84%. | StockAnalysis statistics and Macrotrends stock history | July 12, 2026 |
| Forward forecast reference | StockAnalysis reported a 2026 revenue forecast of $630.46 million, 2027 revenue forecast of $793.00 million, 2026 EPS forecast of negative $0.51, and 2027 EPS forecast of $0.44. The analyst price target range was $138 to $170, with a $158.31 average. | StockAnalysis forecast, S&P Global, and TipRanks data | July 12, 2026 |
| Three-scenario sensitivity | Using the $0.44 2027 EPS forecast as a forward proxy, 60%/40%/10% annual growth, and 150x/120x/80x terminal multiples over three years, financial_rigor.py produced $270.30 bullish, $144.90 base, and $46.90 bearish outputs. These assumptions are illustrative and not company guidance. | financial_rigor.py three-scenario calculation and StockAnalysis forecast | July 12, 2026 |
This GKOS AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a promise of future return. Forecast scenarios are based on available public data as of July 12, 2026 and can be wrong if Glaukos fundamentals, product adoption, reimbursement, regulation, clinical evidence, cash flow, share count, market price, or investor sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
